"Ethics filings revealed several thousand trades on the US president's behalf tied to stocks and bonds in the first quarter of 2026, with a cumulative value of between $220m and around $750m. The forms, released last week, included securities linked to some of the largest companies in the US, including Apple, Boeing, Goldman Sachs, Meta Platforms, Microsoft and Nvidia."
"Among the trades made on Trump's behalf were seven acquisitions of shares in Eli Lilly worth up to $680,000 between 6 January and the end of March, while federal agencies rolled out some initiatives that benefited the drugmakers's weight-loss drugs. KFF Health News, which highlighted the transactions, noted that during and just after the same time period several US government actions under Trump benefited Eli Lilly's GLP-1 business."
"This includes a pilot program in which the Centers for Medicare & Medicaid Services will expand access to GLP-1 medications, including Lilly's Foundayo and Zepbound KwikPen, for Medicare patients. And in February, KFF Health News noted, the administration unveiled TrumpRx: its direct-to-consumer drug sales website, aimed at lowering prescription drug costs."
"According to a White House fact sheet, for the first few months TrumpRx featured medications made by the first five manufacturers that struck pricing deals with the administration including Eli Lilly and pointed patients to Lilly. The Trump Organization has denied the president plays any role in selecting the stocks in his investment portfolio."
Financial disclosures show thousands of securities trades made on Donald Trump’s behalf in the first quarter of 2026, with a cumulative value reported between $220 million and about $750 million. The trades included holdings linked to major US companies such as Apple, Boeing, Goldman Sachs, Meta Platforms, Microsoft, and Nvidia. Eli Lilly received multiple share acquisitions worth up to $680,000 between January 6 and the end of March. During and shortly after the same period, federal actions benefited Eli Lilly’s GLP-1 business, including a Centers for Medicare & Medicaid Services pilot program expanding access to GLP-1 medications for Medicare patients. The administration also launched TrumpRx, a direct-to-consumer drug sales website featuring medications from manufacturers that reached pricing deals, including Eli Lilly.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]